An expert panel convened to discuss the evolving treatment and diagnostic landscape of NMIBC. Moderated by Sia Daneshmand, MD, University of Southern California, the roundtable consisted of Mark D. Tyson, MD, Mayo Clinic; Aaron Berger, MD, Associated Urological Specialists; and Vignesh T. Packiam, MD, Rutgers Cancer Institute.
In the first segment of the discussion, the panel discusses a wave of bladder cancer therapies—including cretostimogene, gem/doce, and AI-driven biomarkers—highlighting the excitement around new data, treatment sequencing, and the potential of combination strategies to improve bladder preservation.